Value-Based Pricing Incentive for Innovation or Zero Net Benefit?

被引：31

作者：

Hughes, Dyfrig A. ^{[1
]}

机构：

[1] Bangor Univ, Ctr Hlth Econ & Med Evaluat, Inst Med & Social Care Res, Bangor LL57 1UT, Gwynedd, Wales

来源：

PHARMACOECONOMICS | 2011年 / 29卷 / 09期

基金：

英国医学研究理事会;

关键词：

DRUGS; NICE; UK;

D O I：

10.2165/11592570-000000000-00000

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

[No abstract available]

引用

页码：731 / 735

页数：5

共 31 条

[1]

*ALL WAL MED STRAT, 2011, GUID APPR MED

[2]

[Anonymous], GUID METH TECHN APPR

[3]

[Anonymous], 2004, PRIORITY MED EUROPE

[4]

CLAXTON K, 60 U YORK CTR HLTH E

[5] Value based pricing for NHS drugs: an opportunity not to be missed? [J].

Claxton, Karl ;

Lindsay, Andrew Briggs ;

Buxton, Martin J. ;

Culyer, Anthony J. ;

McCabe, Christopher ;

Walker, Simon ;

Sculpher, Mark J. .

BMJ-BRITISH MEDICAL JOURNAL, 2008, 336 (7638) :251-254

[6] OFT, VBP: QED? [J].

Claxton, Karl .

HEALTH ECONOMICS, 2007, 16 (06) :545-558

[7]

*DEP HLTH ASS BRIT, PHARM PRIC REG SCH 2

[8]

Department of Health, 2010, NEW VAL BAS APPR PRI

[9] Generic and therapeutic substitutions in the UK: are they a good thing? [J].

Duerden, Martin G. ;

Hughes, Dyfrig A. .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (03) :335-341

[10] NICE and new: appraising innovation [J].

Ferner, Robin E. ;

Hughes, Dyfrig A. ;

Aronson, Jeffrey K. .

BMJ-BRITISH MEDICAL JOURNAL, 2010, 340

← 1 2 3 4 →